drugset / Trial / NCT01369303

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

NCT01369303

Phase 1 Completed 194 enrolled CONRAD
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of the study is to obtain data on the pharmacokinetics (PK) and pharmacodynamics (PD) and immune system effect of the BAT24 dosing regimen versus daily and pericoital dosing regimens with vaginal use of tenofovir 1% gel after a single sex act and after multiple sex acts.

Timeline

Start
2012-01
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir Small molecule 1 % Other

Indications

No indication recorded.